Form 4: Natera CEO Chapman Reports RSU Grant, Stock Sales

Natera CEO Steven Leonard Chapman reported the grant of 37,401 Restricted Stock Units and subsequent sales of 3,950 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Steven Leonard Chapman, CEO and President of Natera, Inc., reported changes in his beneficial ownership of common stock.
• On February 27, 2026, Mr. Chapman was issued 37,401 Restricted Stock Units (RSUs).
• These RSUs represent a contingent right to receive one share of Natera's Common Stock each.
• The RSUs will vest over four years, with 25% vesting on March 1, 2027, and the remaining RSUs vesting in 12 equal quarterly installments thereafter.
• On March 2, 2026, Mr. Chapman sold a total of 3,950 shares of common stock in three separate transactions.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2023, and amended on December 2, 2024.
• The shares were sold at weighted average prices of $199.1737 (1,122 shares), $200.2406 (2,463 shares), and $201.1767 (365 shares).
• Following these transactions, Mr. Chapman beneficially owns 156,607 shares of Natera's common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive due to the significant RSU grant, which incentivizes long-term performance, partially offset by routine sales under a pre-established 10b5-1 plan.

Positives

• The grant of 37,401 Restricted Stock Units (RSUs) to the CEO aligns management's long-term interests with shareholders, as the units vest over four years.

Negatives

• The sale of 3,950 shares by the CEO, even under a pre-arranged 10b5-1 plan, reduces his direct ownership in the company.

Future Outlook

The granted Restricted Stock Units (RSUs) are scheduled to vest over four years, with the first 25% vesting on March 1, 2027, and the remainder in 12 equal quarterly installments thereafter, indicating a long-term incentive structure for the CEO.

Industry Context

StockSavvy.ai notes that insider transactions, such as RSU grants and sales under 10b5-1 plans, are common in the biotechnology and diagnostics industry. While RSU grants are a standard compensation tool to align executive interests with long-term shareholder value, pre-arranged sales plans provide executives with a mechanism to diversify their holdings in a compliant manner, reducing potential concerns about trading on non-public information.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grant aligns the CEO's long-term incentives with shareholder value creation. The sales, while planned, represent a reduction in direct insider ownership, which some investors may monitor.

Next Steps

• The vesting of 25% of the granted Restricted Stock Units on March 1, 2027.
• Subsequent quarterly vesting of the remaining RSUs over the following three years.

Key Dates

Keywords

Natera, NTRA, Form 4, insider trading, RSU, stock sale, CEO, Steven Chapman, 10b5-1 plan